Imbruvica achieves 67% ORR in chronic graft-versus-host-disease

6 December 2016

Janssen Research and Development, a subsidiary of the US health care giant Johnson & Johnson (NYSE: JNJ), has presented Phase II data on Imbruvica (ibrutinib) in chronic graft-versus-host-disease (cGVHD), who failed prior systemic therapy.

The findings, presented at the 58th American Society of Hematology (ASH) Annual Meeting, show that ibrutinib demonstrated clinically meaningful and durable responses and reduced symptom severity, with an overall response rate (ORR) of 67% in patients with this life-threatening consequence of stem cell or bone marrow transplant.

"We look forward to further exploring the potential of ibrutinib as initial therapy for this serious condition with the initiation of a Phase III trial in the first-line setting"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK